Given that metabolic syndrome is a recognized risk factor for pancreatitis, irbesartan may indirectly elevate the risk of pancreatitis by influencing insulin metabolic pathways (Badalov et al., 2007). This evidence concerns the gene INS and metabolic syndrome.